Nonviral gene delivery to human ovarian cancer cells using arginine-grafted PAMAM dendrimer

Drug Development and Industrial Pharmacy

Volumn 37, Issue 1, 2011, Pages 41-46

  Jang, Soo Hyun ^a   Choi, Su Jin ^a   Oh, Ji Hyun ^a   Chae, Song Wha ^a   Nam, Kihoon ^b   Park, Jong Sang ^b   Lee, Hwa Jeong ^a  

^a Ewha Womans University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Antisense gene; Cancer gene therapy; Epidermal growth factor receptor; L arginine grafted polyamidoamine dendrimer; Polyethyleneimine; Thymidine incorporation

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR; LUCIFERASE; POLYAMIDOAMINE; POLYETHYLENEIMINE;

ANTISENSE THERAPY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONVIRAL GENE DELIVERY SYSTEM; OVARY CARCINOMA;

ARGININE; CELL PROLIFERATION; DENDRIMERS; DNA, ANTISENSE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LUCIFERASES; MODELS, MOLECULAR; OVARIAN NEOPLASMS; POLYETHYLENEIMINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 78649986679     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.489563     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2006). Cancer statistics, 2006. Cancer J Clin, 56:106-30.
2. DiSaia PJ, Bloss JD. (2003). Treatment of ovarian cancer: New strategies. Gynecol Oncol, 90:S24-32.
3. Bartlett JM, Langdon SP, Simpson BJ. (1996). The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer, 73:301-6.
4. Nicholson RI, Gee JM, Harper ME. (2001). EGFR and cancer prognosis. Eur J Cancer, 37(Suppl. 4):S9-15.
5. Ranson M. (2002). ZD1839 (Iressa): For more than just nonsmall cell lung cancer. Oncologist, 7(Suppl. 4):16-24.
6. Raymond E, Faivre S, Armand JP. (2000). Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs, 60(Suppl. 1):15-23.
7. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. (2001). Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst, 93:1375-84.
8. Thomas M, Ge Q, Lu JJ, Chen J, Klibanov AM. (2005). Crosslinked small polyethylenimines: While still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res, 22:373-80.
9. Li S, Huang L. (2000). Nonviral gene therapy: Promises and challenges. Gene Ther, 7:31-4.
10. Huang L, Li S. (1997). Liposomal gene delivery: A complex package. Nat Biotechnol, 15:620-1.
11. Schatzlein AG. (2001). Non-viral vectors in cancer gene therapy: Principles and progress. Anticancer Drug, 2:275-304.
12. Lollo CP, Banaszczyk MG, Chiou HC. (2000). Obstacles and advances in non-viral gene delivery. Curr Opin Mol Ther, 2:136-42.
13. Malhotra M, Kulamarva A, Sebak S, Paul A, Bhathena J, Mirzaei M, et al. (2009). Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm, 35:719-26.
14. Pouton CW, Seymour LW. (2001). Key issues in non-viral gene delivery. Adv Drug Deliv Rev, 46:187-203.
15. Schmidt-Wolf GD, Schmidt-Wolf IG. (2003). Non-viral and hybrid vectors in human gene therapy: An update. Trends Mol Med, 9:67-72.
16. Heansler J, Szoka FC. (1997). A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells. Gene Ther, 4:823-32.
17. Choi JS, Nam K, Park J, Kim JB, Lee JK, Park J. (2004). Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. J Control Release, 99:445-56.
18. Kim JB, Choi JS, Nam K, Lee M, Park JS, Lee JK. (2006). Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release, 10:110-7.
19. Boado RJ, Pardridge WM. (1998). Ten nucleotide cis element in the 3'-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. Mol Brain Res, 59:109-13.
20. Zhang Y, Lee HJ, Boado RJ, Pardridge WM. (2002). Receptormediated delivery of an antisense gene to human brain cancer cells. J Gene Med, 4:183-94.
21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 82:1107-12.
22. Favaro E, Indraccolo S. (2007). Gene therapy of cancer in the clinic: Good news in sight from Asia? Curr Opin Mol Ther, 9:477-82.
23. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci U S A, 92:7297-301.
24. Kichler A. (2004). Gene transfer with modified polyethylenimines. J Gene Med, 6:S3-10.
25. Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I, et al. (2002). Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer, 98:645-50.
26. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. (1999). PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther, 6:595-605.
27. Zhong H, He ZG, Li Z, Li GY, Shen SR, Li XL. (2008). Studies on polyamidoamine dendrimers as efficient gene delivery vector. J Biomater Appl, 22:527-44.
28. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. (2003). In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials, 24:1121-34.
29. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A. (2003). The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm, 252:263-6.